Page last updated: 2024-12-07

ra 263

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RA 263: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100145
MeSH IDM0108224

Synonyms (22)

Synonym
1h-imidazole, 1-(2,3-dideoxy-alpha-d-erythro-hex-2-enopyranosyl)-2-nitro-
brn 5759589
nsc 342714
1-(2,3-dideoxy-alpha-d-erythro-hex-2-enopyranosyl)-2-nitro-1h-imidazole
1-(2,3-dideoxy-beta-d-erythro-hex-2-enopyranosyl)-2-nitro-1h-imidazole
1h-imidazole, 1-(2,3-dideoxy-beta-d-erythro-hex-2-enopyranosyl)-2-nitro-
82225-31-8
nsc364383
nsc-342714
nsc-364383
ra 263
82205-95-6
mls003389343 ,
nsc342714
2-(hydroxymethyl)-6-(2-nitroimidazol-1-yl)-3,6-dihydro-2h-pyran-3-ol
smr002048998
ra-263
nsc 364383
1-(2',3'-dideoxy-alpha-d-erythro-hex-2'-enopyranosyl)-2-nitroimidazole
2-(hydroxymethyl)-6-(2-nitro-1h-imidazol-1-yl)-3,6-dihydro-2h-pyran-3-ol
1-(2,3-dideoxyhex-2-enopyranosyl)-2-nitro-1h-imidazole
DTXSID501002553

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The in vitro cytotoxicity data suggested that RA-263 is considerably more toxic to hypoxic cells than misonidazole."( Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
Agrawal, KC; Rockwell, S; Rupp, WD, 1986
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data suggested that RA-263 was eliminated from plasma by a rapid alpha phase and a slower beta phase with T 1/2 of 36 and 72 min, respectively."( Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
Agrawal, KC; Rockwell, S; Rupp, WD, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.64 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]